Phase 4Recruiting

A multicenter, open-label, single-arm clinical study of recombinant human brain natriuretic peptide in the treatment of patients with end-stage heart failure

Sponsor

Shanghai Tenth People's Hospital

Enrolment

180 planned

Conditions

end-stage heart failure

Interventions

Recombinant human brain natriuretic peptide, dosage 0

Ages

adults, older adults

Registry

ChiCTR2600128287

Full record on the Chinese Clinical Trial RegistrySource: WHO ICTRP, processed 20 July 2026